Note 1. Nature of Business Tyme Technologies, Inc. is a Delaware corporation headquartered in New York, NY, with wholly owned subsidiaries, Tyme Inc. and Luminant Biosciences, LLC (Luminant) (collectively, TYME or the Company). Prior to 2014, Luminant conducted the initial research and development of the Companys therapeutic platform. Since January 1, 2014, the majority of the Companys research, development and other business activities have been conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM ) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while maintaining patients quality of life with relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific pathways within cancer, TYMEs therapeutic approach is designed to take advantage of a cancer cells innate metabolic requirements to cause cancer cell death. The Companys lead clinical CMBT compound, SM-88, is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the bodys natural immune system. Clinical trial data have shown that SM-88 has achieved confirmed tumor responses across 15 different cancers, both solid and liquid tumors, including pancreatic, lung, breast, prostate, sarcoma and lymphoma cancers with minimal serious Grade 3 or higher adverse events, which the Company believes is rare for investigational compounds. The Companys lead compound SM-88 is now in a pivotal trial and an adaptive randomized Phase II/III trial with registration intent for patients with second- and third-line pancreatic cancer. In fiscal year 2020, we launched our pivotal study for SM-88 in the third-line treatment of pancreatic cancer through an amendment to our ongoing TYME-88-Panc trial (Part 2); with the first patient dosed in the third quarter of the fiscal year. We anticipate the trial to be fully enrolled by the end of calendar year 2020 or early calendar year 2021. We have also partnered with PanCAN to study SM-88 in an adaptive randomized Phase II/III trial with registration intent known as Precision Promise. Patients are being enrolled in a Phase II study evaluating SM-88 in high-risk sarcomas as well. The Company is actively evaluating the expansion of our clinical program to hematological, breast, prostate and other cancers. TYME-18 is a CMBT compound under development that is delivered intratumorally. Like SM-88, TYME-18 leverages the unique metabolism of cancer to create a treatment for inoperable tumors. Preliminary observations of the local administration of TYME-18, an amphiphilic steroid acid, suggested its potential as an important regulator of energy metabolism that may impede the ability of tumors to increase in size which could prove useful in difficult-to-treat cancers. In initial preclinical xenograft mouse studies, TYME-18 was able to completely resolve over 90 percent (11/12 mice) of established colorectal tumors within 12 days versus an average of over 600 percent growth in the control animals. The Company plans to continue with the development of TYME-18 in solid tumors and to provide details of an IND-enabling program this calendar year. The accompanying consolidated financial statements include the results of operations of Tyme Technologies, Inc. and its wholly-owned subsidiaries. Liquidity The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. In April 2019, the Company raised net proceeds of $11.3 million after underwriting discounts and before expenses through an underwritten registered offering. On October 18, 2019, TYME entered into an Open Market Sale Agreement SM (the Sale Agreement) with Jefferies LLC (Jefferies) as sales agent, pursuant to which the Company may, from time to time, sell shares of Common Stock through Jefferies having an aggregate offering price of up to $30.0 million (the Jefferies ATM). In the year ended March 31, 2020, the Company raised approximately $1.7 million in aggregate gross proceeds before commissions and expenses through the Sale Agreement and paid commissions and expenses of $0.2 million. At March 31, 2020, there remained approximately $28.3 million of availability to sell shares through the Jefferies ATM. On January 7, 2020, the Company entered into a Securities Purchase Agreement with Eagle Pharmaceuticals, (Eagle), pursuant to which the Company raised $20,000,000 through the issuance and sale to Eagle of 10,000,000 shares of Common Stock, at a price of $2.00 per share. The proceeds of the aforementioned offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the year ended March 31, 2020, the Company had negative cash flow from operations of $19.6 million and net loss of $22.0 million, which included $2.4 million of net non-cash charges, primarily non-cash equity compensation expense partially offset by income from change in fair value of warrant liability. As of March 31, 2020, the Company had working capital of approximately $22.5 million. Management has concluded that substantial doubt does not exist regarding the Companys ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Companys assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Companys operations, and potential adverse conditions or events as of the issuance date of these financial statements.